People on the Move: Specialty Companies
Kenneth I. Moch has been appointed president and CEO of Cognition Therapeutics Inc. Prior to joining Cognition, Moch was a managing partner of The Salutramed Group, a strategy consulting firm. He brings to Cognition more than 25 years of experience in creating, managing and financing biomedical companies, having previously served as president and CEO of Chimerix Inc., Alteon Inc., Biomedical Enterprises, and Biocyte Corporation. Moch was also co-founder and VP of The Liposome Company Inc. Cognition Therapeutics is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease-modifying small molecule drug candidates which are being developed to treat Alzheimer’s disease and potentially other neurocognitive disorders.
Jesse Ledger was made president of Nuvo Pharmaceuticals Inc. Ledger was previously Nuvo’s VP of business development. John London, who was Nuvo’s president and CEO, will continue to lead the company as its CEO. Nuvo is a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities.
Fred R. Seddiqui is now CEO of Helix Twelve Pharmaceuticals Inc. Seddiqui brings more than 30 years of industry experience to Helix Twelve. He has held various global executive positions in medical device and biotechnology companies. Over the past three years, Seddiqui has served as an executive advisor to Helix Twelve and is a member of the board of directors. Helix Twelve Pharmaceuticals is focused on the development of precision therapeutics in areas including women’s health, heart disease, and cancer.
Dan Chicoine has been appointed CEO on an interim basis for Crescita Therapeutics Inc. He replaces Greg Orleski. Chicoine will also continue to serve as the company’s executive chairman. Crescita is a commercial dermatology company with a portfolio of over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms.
Chris LeMasters was appointed to the newly created position of executive VP and chief business officer of Mirati Therapeutics Inc. Before joining Mirati, LeMasters served as the CEO of Promosome. Mirati is developing a pipeline of targeted oncology products intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs.
Mark A. McPartland was made VP, Corporate Development and Investor Relations, at VistaGen Therapeutics Inc. Prior to joining VistaGen, McPartland served as the VP of Corporate Development and Communications at Stellar Biotechnologies Inc. VistaGen is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with CNS diseases and disorders.
Keith Kennedy is now chief financial officer of Veracyte Inc. Kennedy previously was president and CEO of MCG Capital Corp. He succeeded Shelly Guyer, who earlier this year announced her plan to step down as CFO and has continued in the role to ensure a smooth transition. Veracyte is a genomic diagnostics company.
Jeff Elliott has become chief financial officer of Exact Sciences Corp. Elliott, a former senior research analyst at Robert W. Baird & Co., joined Exact Sciences as VP, business development and strategy, in June 2016. Exact Sciences is the manufacturer of Cologuard, the first noninvasive screening test for colorectal cancer.
David L. Lowrance, CPA, was appointed chief financial officer at Savara Pharmaceuticals. Prior to joining Savara, Lowrance served as the chief financial officer for Edgemont Pharmaceuticals. Savara Pharmaceuticals is an emerging specialty pharmaceutical company focused on rare respiratory diseases.
Christophe Bonny, Ph.D. is now chief scientific officer of Enterome Biosciences SA. Dr. Bonny was previously chief scientific officer at Bicycle Therapeutics and before that he worked at Switzerland-based Xigen where he served as chief scientific officer and president. Enterome is a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome.
Patrick Shea has become chief commercial officer of Egalet Corp. Before joining Egalet, Shea served as chief commercial officer at Clarus Therapeutics Inc. Egalet is a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.
Alexandra D.J. Mancini, M.Sc., was made senior VP, Clinical and Regulatory Affairs, at InMed Pharmaceuticals Inc. In addition to her activities via her private consulting company True North Synergy, Mancini has been an executive with several biotech companies, overseeing a wide range of drug development activities. InMed is a preclinical stage company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
Gregory L. Larkin, M.D., MS, MSPH, FACEP, FACEM has joined Nevakar LLC in the newly created position of VP, Clinical Development. In addition to his role at Nevakar, Dr. Larkin is currently adjunct professor of psychiatry at New York University School of Medicine. Nevakar is a specialty pharmaceutical company focused on therapies within the injectable and ophthalmic space.
Helen Stefanovic is director of regulatory affairs at Nexus BioPharma Inc. Stefanovic served as manager, Science Policy, Corporate Strategic Planning and Policy at Pfizer Inc. Nexus BioPharma is developing a new weight loss drug.
David Moskowitz is appointed to the newly created position of VP, Strategy and Corporate Communications, at Biocept Inc. Moskowitz was VP, Investor Relations, at Trovagene. Biocept is a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment.